Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer

被引：0
|
作者：
Gupta, Shilpa
Munster, Pamela N.
Hollebecque, Antoine
Argues, Guillem
Dajanl, Olav
Chang, Jonathan D.
Swift, Ann M.
Tosolini, Alessandra
Piha-Paul, Sarina Anne
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Merck & Co Inc, Whitehouse Stn, NJ USA
[7] Merck & Co Inc, N Wales, PA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2509
引用
收藏
页数：1
相关论文
共 49 条
  • [41] A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)
    Ma, C. X.
    Suman, V. J.
    Goetz, M.
    Northfelt, D.
    Burkard, M.
    Ademuyiwa, F.
    Naughton, M.
    Margenthaler, J.
    Aft, R.
    Gray, R.
    Tavaarwerk, A.
    Wilke, L.
    Haddad, T.
    Moynihan, T.
    Loprinzi, C.
    Hieken, T.
    Hoog, J.
    Guo, Z.
    Han, J.
    Vij, K.
    Mardis, E.
    Sanati, S.
    Al-Kateb, H.
    Doyle, L.
    Erlichman, C.
    Ellis, M. J.
    CANCER RESEARCH, 2016, 76
  • [42] Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1 positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
    Rugo, H. S.
    Delord, J-P
    Im, S-A
    Ott, P. A.
    Piha-Paul, S. A.
    Bedard, P. L.
    Sachdev, J.
    Le Tourneau, C.
    van Brummelen, E.
    Varga, A.
    Saraf, S.
    Pietrangelo, D.
    Karantza, V.
    Tan, A.
    CANCER RESEARCH, 2016, 76
  • [43] Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding
    Siu, Lillian L.
    De Bono, Johann
    Wisinski, Kari B.
    Higano, Celestia S.
    Cook, Natalie
    Luken, Maria Jose De Miguel
    Kumar, Rajiv
    Lang, Joshua
    Chatta, Gurkamal S.
    Tolaney, Sara M.
    Symeonides, Stefan M.
    Morrison, Gilmour
    Mitchell, Patrick D.
    Brooks, David G.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2015, 75
  • [44] BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER plus ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
    Turner, N.
    Alarcon, E.
    Armstrong, A.
    Philco, M.
    Lopez Chuken, Y. A.
    Sablin, M-P.
    Tamura, K.
    Gomez Villanueva, A.
    Perez-Fidalgo, J. A.
    Foxley, A.
    Lindemann, J.
    Maudsley, R.
    Outhwaite, E.
    Pass, M.
    Rugman, P.
    Schiavon, G.
    Oliveira, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2-breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
    Zhang, P.
    Xu, B.
    Sun, T.
    Wang, Y.
    Li, W.
    Tong, Z.
    Phadke, S.
    Feinstein, T. M.
    Qu, J.
    Guo, P.
    Ma, W.
    Zhang, M.
    Yue, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S373 - S374
  • [46] Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER -positive (ER plus ) metastatic breast cancer (MBC)
    Juric, D.
    Argiles, G.
    Burns, H. A.
    Gonzalez-Angulo, A. M.
    Saura, C.
    Quadt, C.
    Douglas, M.
    Demanse, D.
    De Buck, S.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [47] Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
    Arpino, G.
    Ferrero, J-M
    de la Haba-Rodriguez, J.
    Easton, V.
    Schuhmacher, C.
    Restuccia, E.
    Rimawi, M.
    CANCER RESEARCH, 2017, 77
  • [48] Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
    Arpino, Grazia
    de la Haba-Rodriguez, Juan
    Ferrero, Jean-Marc
    De Placido, Sabino
    Klingbiel, Dirk
    Revelant, Valentine
    Wohlfarth, Christine
    Poppe, Raf
    Rimawi, Mothaffar F.
    CANCER RESEARCH, 2021, 81 (04)
  • [49] AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate
    Lillian, S.
    De Bono, J.
    Higano, C.
    Shapiro, G.
    Brugger, W.
    Mitchell, P.
    Colebrook, S.
    Klinowska, T.
    Barry, S.
    Dean, E.
    Martin-Mills, J.
    Wisinski, K.
    Moorthy, G.
    Mills, J.
    Cruzalegui, F.
    Tolaney, S.
    Lang, J.
    Luken, M. Jose De Miguel
    Kunar, R.
    Chatta, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S19 - S19
12345